PIK3CA and colorectal carcinoma: Nevertheless, the mechanisms underlying the inhibitory responses are still not well understood, namely in the context of CRC with mutations in KRAS. Therefore, and taking into consideration the above mentioned results, we tested the recently developed PI3K p110α inhibitor, BYL719.